Adam Rogers

Chief Executive Officer, NervGen Pharma

Search every verified Adam Rogers interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Adam Rogers, chairman, president, and CEO of NervGen Pharma, discussed the company's strategy and progress in a podcast interview. He described his approach since becoming CEO the previous July, which included moving the company's trading from Canada's TSX Venture Exchange to the NASDAQ for greater visibility and making key hires for growth. Rogers stated that the company's goal is to commercialize its lead candidate, NVG-291, a daily neuroreparative peptide for spinal cord injury, rather than sell the company. Rogers reported early trial results for NVG-291, noting an 825% improvement in hand function from day zero to week 12 in patients, as measured by the GRASSP test. He also mentioned that the drug is a 35-amino acid peptide administered via daily abdominal injection, which can be self-administered at home. Rogers said the company is on the verge of entering phase three trials and is building the delivery infrastructure for the drug, as no therapeutic currently exists for spinal cord injury.